HIGHLIGHTS
- who: Matteo Santoni and collaborators from the Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni, Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona have published the article: Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?, in the Journal: (JOURNAL)
- what: In 2019, the authors reported the results of an international retrospective real-world analysis on cabozantinib in previously treated patients with metastatic RCC, which was aimed at investigating the presence of prognostic factors in this context .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.